Chemed

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Chemed reports strong Q1 performance, optimistic about growth trajectory

Chemed's Q1 2023 earnings call highlighted a positive performance trajectory post-pandemic, with a focus on VITAS' growth and operational strategies. The company addressed challenges related to Medicare reimbursement rates and emphasized opportunities for further expansion and staff satisfaction.

Chemed's VITAS shines, Roto-Rooter adapts to consumer challenges

Chemed's Q2 2023 earnings call highlighted VITAS' strong performance and operational improvements post-pandemic.
Roto-Rooter faced challenges in consumer spending but focused on enhancing online presence and conversion rates.
Both segments showcased resilience amidst economic headwinds, with strategic initiatives in place to drive growth and operational efficiency.
Chemed's strategic cost management and revenue generation strategies position the company for sustainable growth and margin protection.

Chemed reports strong Q3 performance, eyes growth amid economic challenges

Chemed's diversified business segments showed resilience and growth potential, with VITAS Healthcare and Roto-Rooter both demonstrating strengths and addressing challenges. The company remains cautiously optimistic about 2024, focusing on operational efficiency and market dynamics for sustained performance.

Chemed's VITAS shines in Q4 with strong growth, Roto-Rooter faces challenges

Chemed's VITAS segment excelled with strong revenue growth and operational improvements, while Roto-Rooter faced challenges in call volume.
Management's confidence in sustained growth and margin improvement presents opportunities for both VITAS and Roto-Rooter in 2024.
Strategies to address challenges and capitalize on opportunities will be crucial for Chemed's divisions to meet their forecasted targets.
Overall, Chemed's performance in Q4 2023 sets a positive tone for the company's outlook and strategic initiatives moving forward.

Chemed excels in hospice segment, Roto-Rooter faces commercial challenges

Chemed's VITAS segment outperformed, while Roto-Rooter faced challenges, prompting strategic actions to enhance commercial performance and drive growth.

Chemed's VITAS shines in Q2 2024, Roto-Rooter faces revenue challenges

Chemed's VITAS segment is driving revenue growth and margin expansion, while Roto-Rooter faces challenges in revenue decline. The company aims to capitalize on growth opportunities in the hospice services sector.

Chemed's VITAS shines amid Roto-Rooter's challenges in Q3 2024

Chemed's earnings call showcased VITAS' resilience and growth prospects, while addressing Roto-Rooter's challenges and strategic adjustments. The company remains optimistic about adjusted net income outlook for the year.

Chemed reports strong Q4 performance, navigates Medicare cap challenges

Chemed's Q4 earnings call showcased robust performance, with VITAS and Roto-Rooter demonstrating resilience and strategic planning amidst challenges. The company's commitment to shareholder returns and growth strategies positions it well for the future.

Chemed's VITAS Healthcare and Roto-Rooter Shine in Q1 2025

Chemed's subsidiaries, VITAS Healthcare and Roto-Rooter, delivered strong results in Q1 2025, with VITAS showing robust growth in admissions and net revenue. While facing cash flow challenges, the company is focused on strategic opportunities for growth and operational efficiency.

Chemed reports mixed Q2 results, eyes growth in healthcare segment

Chemed's Q2 2025 performance was mixed, with VITAS showing growth while Roto-Rooter faced revenue challenges. The company's strengths lie in VITAS' revenue and census growth, but challenges persist in Roto-Rooter's performance. Chemed has opportunities to improve Roto-Rooter's operations and leverage VITAS' growth for overall success in 2025.

Chemed reports mixed Q3 results, targets margin improvement in 2026

Chemed reported mixed performance with revenue growth but declining EBITDA for VITAS and Roto-Rooter segments. The company is focused on margin improvement strategies and anticipates better margins and revenue growth in 2026. Chemed's proactive approach to addressing challenges and pursuing growth opportunities reflects a strategic outlook. Overall, Chemed remains optimistic about its performance and future prospects, emphasizing a positive trajectory.

Chemed reports mixed Q4 performance, VITAS shows growth potential

Chemed's subsidiaries had a mixed performance in Q4 2025, with VITAS showing improvements. VITAS aims for sustained growth in 2026, while Roto-Rooter focuses on improving margins. Management is confident in meeting guidance despite challenges faced by Roto-Rooter. Both subsidiaries have opportunities to enhance performance and overcome current challenges.